End to End Oncology Lab Solutions for Better Outcomes for the Oncology Drug Development
The complexity of oncology clinical trials require a partner that provides laboratory services throughout the development continuum. Teddylab understands the complex biology of cancer and the associated with scientific networks that are able to deliver valuable insights in order to shape better outcomes.
Teddylab has developed expertise and capabilities that can uniquely support oncology studies with end-to-end oncology lab solutions. This includes assisting the design of smarter studies by suggesting the right technology for the right test is incorporated into clinical development programs. With experience in anatomic and molecular pathology, flow cytometry, immunoassay and genomics-based assay development, Teddylab can provide customized, integrated lab solutions for oncology drug development.
Precision Medicine : teddylab has the experience and capabilities to design and develop the innovative assays that targeting new biomarkers for tumor classification and patient stratification, for instance, HER2, C-MET, FGFR, KRAS (G12C), IDH1/2, EZH2, EGFR, ALK, ROS1, BRAF, HRD, etc.
Immunotherapy: Refers to the treatment of the body's low or hyperactive immunity, artificially enhancing or suppressing the body's immune function to achieve the purpose of treating the disease. Common biomarkers include TMB, MSI, TME, etc.
Cell Therapy: This is a new type of precision targeted therapy for the treatment of tumors. Through genetic engineering technology, T cells are activated to specifically recognize tumor cells in the body, and release a large number of various effectors through immunization which can efficiently kill tumor cells so as to achieve the purpose of treating malignant tumors. Common biomarkers: BCMA, CD19, TCR, etc. Related detections include VCN, RCL, RCR and lentiviral site insertion.
Teddylab provides end to end solutions for oncology study:
- Equipped with two major sequencing platforms, Thermo and Illumina, Teddylab provides pan-solid tumor and liquid biopsy test services covering all relevant biomarker test for targeted therapy, immunotherapy and cell therapy
- Equipped with a classic next-generation sequencing platform, Teddylab provides pan-solid tumor test services, suitable for C-MET and MSI biomarker
- Equipped with two rt-PCR, Thermo and Roche, Teddylab provides pan-solid tumor and liquid biopsy test services, suitable for IDH1/2, EZH2, EGFR, ALK, ROS1, KRAS, BRAF, TME and cell therapy related VCN and RCL test
- Equipped with Bio-rad ddPCR, Teddylab provides pan-solid tumor and liquid biopsy test services, suitable for KRAS (G12C), HER2, EGFR and cell therapy related VCN test+D4